186 related articles for article (PubMed ID: 12442064)
1. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
Olsson PO; Lindström T
Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
[TBL] [Abstract][Full Text] [Related]
2. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
[TBL] [Abstract][Full Text] [Related]
3. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
4. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
Ligthelm RJ; Mouritzen U; Lynggaard H; Landin-Olsson M; Fox C; le Devehat C; Romero E; Liebl A
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):511-9. PubMed ID: 17115349
[TBL] [Abstract][Full Text] [Related]
5. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
Fajardo Montañana C; Hernández Herrero C; Rivas Fernández M
Diabet Med; 2008 Aug; 25(8):916-23. PubMed ID: 18959604
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
Davies MJ; Thaware PK; Tringham JR; Howe J; Jarvis J; Johnston V; Kitchener DL; Skinner TC; McNally PG; Lawrence IG
Diabet Med; 2007 Jul; 24(7):714-9. PubMed ID: 17403126
[TBL] [Abstract][Full Text] [Related]
7. [Medication use in diabetes mellitus (VI). Economics and effectiveness of insulin and sulfonyl-urea combination therapy compared with conventional two daily doses].
Costa B; Estopá A; Borrás J; Sabaté A
Med Clin (Barc); 1998 Nov; 111(15):568-72. PubMed ID: 9859089
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
Johnson JL; Wolf SL; Kabadi UM
Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
[TBL] [Abstract][Full Text] [Related]
9. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
[TBL] [Abstract][Full Text] [Related]
10. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
11. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
[TBL] [Abstract][Full Text] [Related]
12. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
Hausmann M; Dellweg S; Osborn C; Heinemann L; Buchwald A; Rosskamp R; Genova P; Heise T
Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
[TBL] [Abstract][Full Text] [Related]
13. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
Robertson KJ; Schoenle E; Gucev Z; Mordhorst L; Gall MA; Ludvigsson J
Diabet Med; 2007 Jan; 24(1):27-34. PubMed ID: 17227321
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus.
Kabadi MU; Kabadi UM
Ann Pharmacother; 2003 Nov; 37(11):1572-6. PubMed ID: 14565810
[TBL] [Abstract][Full Text] [Related]
15. Insulin therapy in type 2 diabetes: what is the evidence?
van Avendonk MJ; Rutten GE
Diabetes Obes Metab; 2009 May; 11(5):415-32. PubMed ID: 19175375
[TBL] [Abstract][Full Text] [Related]
16. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study.
Hohberg C; Pfützner A; Forst T; Lübben G; Karagiannis E; Borchert M; Schöndorf T
Diabetes Obes Metab; 2009 May; 11(5):464-71. PubMed ID: 19422402
[TBL] [Abstract][Full Text] [Related]
17. Type II diabetic subjects with secondary failure: treatment with prebreakfast mixed ultralente and regular insulin with a sulfonylurea.
Kabadi UM; Kabadi MU
J Fam Pract; 1991 Oct; 33(4):349-53. PubMed ID: 1919450
[TBL] [Abstract][Full Text] [Related]
18. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure.
Landstedt-Hallin L; Adamson U; Arner P; Bolinder J; Lins PE
Diabetes Care; 1995 Aug; 18(8):1183-6. PubMed ID: 7587856
[TBL] [Abstract][Full Text] [Related]
19. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
Diabet Med; 2003 Nov; 20(11):935-41. PubMed ID: 14632720
[TBL] [Abstract][Full Text] [Related]
20. Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
Clauson P; Karlander S; Steen L; Efendic S
Diabet Med; 1996 May; 13(5):471-7. PubMed ID: 8737030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]